6,268 Shares in Waters Corporation $WAT Purchased by Bryn Mawr Trust Advisors LLC

Key Points

• Bryn Mawr Trust Advisors acquired 6,268 shares of Waters Corporation in the second quarter, valued at approximately $2.35 million. Institutional investors collectively own 94.01% of the company.
• Waters exceeded quarterly expectations, reporting adjusted earnings of $3.05 per share versus the $3.01 consensus and revenue of $1.65 billion. Revenue increased 113.3% year over year, and the company issued fiscal 2026 EPS guidance of $14.45–$14.65.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $420.35, while targets range as high as $460. Shares recently opened at $411.88, near their 52-week high of $420.26.

Bryn Mawr Trust Advisors LLC acquired a new stake in shares of Waters Corporation (NYSE:WAT - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,268 shares of the medical instruments supplier's stock, valued at approximately $2,351,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pinnacle Associates Ltd. lifted its stake in Waters by 0.3% during the 4th quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier's stock valued at $2,890,000 after acquiring an additional 26 shares during the period. Exencial Wealth Advisors LLC grew its stake in shares of Waters by 1.7% in the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier's stock worth $638,000 after acquiring an additional 28 shares during the period. Integrated Wealth Concepts LLC grew its stake in shares of Waters by 2.9% in the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier's stock worth $386,000 after acquiring an additional 30 shares during the period. Clearstead Advisors LLC raised its holdings in shares of Waters by 5.1% during the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier's stock valued at $234,000 after purchasing an additional 30 shares during the last quarter. Finally, Avalon Trust Co raised its holdings in shares of Waters by 2.3% during the first quarter. Avalon Trust Co now owns 1,330 shares of the medical instruments supplier's stock valued at $396,000 after purchasing an additional 30 shares during the last quarter. Institutional investors own 94.01% of the company's stock.

Waters Price Performance

Shares of Waters stock opened at $411.88 on Friday. The stock has a market cap of $40.47 billion, a P/E ratio of 102.71, a P/E/G ratio of 2.40 and a beta of 1.19. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.50 and a current ratio of 1.86. The stock's fifty day moving average is $377.18 and its 200 day moving average is $346.31. Waters Corporation has a one year low of $282.77 and a one year high of $420.26.

Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, topping analysts' consensus estimates of $3.01 by $0.04. Waters had a return on equity of 11.27% and a net margin of 3.58%.The business had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.62 billion. During the same quarter in the prior year, the business posted $2.95 earnings per share. The business's quarterly revenue was up 113.3% on a year-over-year basis. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Sell-side analysts anticipate that Waters Corporation will post 14.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

WAT has been the topic of several research reports. Piper Sandler assumed coverage on shares of Waters in a report on Thursday, June 11th. They issued a "neutral" rating and a $400.00 target price on the stock. Stifel Nicolaus set a $420.00 price target on Waters in a report on Wednesday, August 5th. Barclays raised their price target on Waters from $425.00 to $460.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 5th. Wells Fargo & Company lifted their price objective on Waters from $370.00 to $400.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Finally, Morgan Stanley set a $430.00 price objective on Waters in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Waters currently has a consensus rating of "Moderate Buy" and an average target price of $420.35.

Insider Transactions at Waters

In related news, Director Christopher A. Kuebler sold 3,626 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the sale, the director directly owned 17,808 shares of the company's stock, valued at approximately $7,086,515.52. This represents a 16.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.31% of the company's stock.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source